GGrantIndex
← Leaderboards

Jeffrey D Rothstein

Massachusetts General Hospital

Google Scholar ↗PubMed ↗ORCID ↗
$32,739,978
Attributed
$53,153,276
Total exposure
24
Grants
15
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $9.2M · FY2005–25
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$72,949,315 · 27

By mechanism

R01$29,677,115 · 12
U54$19,125,141 · 5
P01$8,048,126 · 3
RF1$3,816,495 · 1
RC2$3,782,000 · 1
R35$3,647,532 · 1

Top collaborators

Most similar at Massachusetts General Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Neurons”

Research focus

NeuronsCellsAmyotrophic Lateral SclerosisInduced Pluripotent Stem CellAstrocytesNerve DegenerationPathway InteractionsGeneticProteinsBaseNeurodegenerative DisordersCell LineMolecularMotor NeuronsIn VivoCell TypeNeurogliaGenesFunctional DisorderLeadGlutamatesHuntington DiseaseInjuryIn Vitro

Grant awards (137)

Nuclear and Glial Dysfunction in Neurodegeneration$1,228,125
R35 · FY2025 · NS · contact PI
Nuclear pore complex quality control in ALS/FTD$772,375
R01 · FY2025 · NS · contact PI
Nuclear and Glial Dysfunction in Neurodegeneration$1,191,282
R35 · FY2024 · NS · contact PI
Nuclear pore complex quality control in ALS/FTD$772,375
R01 · FY2024 · NS · contact PI
Nuclear pore complex quality control in ALS/FTD$63,650
R01 · FY2024 · NS · contact PI
Nuclear and Glial Dysfunction in Neurodegeneration$1,228,125
R35 · FY2023 · NS · contact PI
Nuclear pore complex quality control in ALS/FTD$772,375
R01 · FY2023 · NS · contact PI
Nuclear pore complex quality control in ALS/FTD$19,541
R01 · FY2023 · NS · contact PI
Nuclear pore complex quality control in ALS/FTD$772,375
R01 · FY2022 · NS · contact PI
Astrocyte Norrin, Norrie disease and Neurodegeneration$442,448
R01 · FY2022 · NS · contact PI
Nuclear pore complex quality control in ALS/FTD$44,108
R01 · FY2022 · NS · contact PI
Nuclear pore complex quality control in ALS/FTD$788,313
R01 · FY2021 · NS · contact PI
Pathophysiology of genetically defined dementia and neurodegeneration: Defining therapeutic targets and pathways$677,625
P01 · FY2021 · NS
Oligodendroglial Dysfunction in C9orf72 ALS and FTD$597,360
R01 · FY2021 · NS · contact PI
Astrocyte Norrin, Norrie disease and Neurodegeneration$442,448
R01 · FY2021 · NS · contact PI
Pathophysiology of genetically defined dementia and neurodegeneration: Defining therapeutic targets and pathways$413,819
P01 · FY2021 · NS
Mitigation of nuclear pore dysfunction in c9FTD/ALS pathogenesis$259,424
P01 · FY2021 · NS · contact PI
Pathophysiology of genetically defined dementia and neurodegeneration: Defining therapeutic targets and pathways$1,091,444
P01 · FY2020 · NS
Nucleocytoplasmic transport and nuclear pore disruption in ALS/FTD$653,024
R01 · FY2020 · NS · contact PI
Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$600,000
U54 · FY2020 · NS
Oligodendroglial Dysfunction in C9orf72 ALS and FTD$597,360
R01 · FY2020 · NS · contact PI
Astrocyte Norrin, Norrie disease and Neurodegeneration$442,448
R01 · FY2020 · NS · contact PI
Mitigation of nuclear pore dysfunction in c9FTD/ALS pathogenesis$259,424
P01 · FY2020 · NS · contact PI
Nuclear Pore Complex and as a Contributor to Tau Associated Dementia$3,816,495
RF1 · FY2019 · AG · contact PI
Pathophysiology of genetically defined dementia and neurodegeneration: Defining therapeutic targets and pathways$1,435,400
P01 · FY2019 · NS
Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$1,422,765
U54 · FY2019 · NS
Nucleocytoplasmic transport and nuclear pore disruption in ALS/FTD$653,024
R01 · FY2019 · NS · contact PI
Oligodendroglial Dysfunction in C9orf72 ALS and FTD$597,360
R01 · FY2019 · NS · contact PI
Regulation of glutamate transport in astrocyte subtypes and in ALS$455,786
R01 · FY2019 · NS
Astrocyte Norrin, Norrie disease and Neurodegeneration$442,448
R01 · FY2019 · NS · contact PI
Mitigation of nuclear pore dysfunction in c9FTD/ALS pathogenesis$348,955
P01 · FY2019 · NS · contact PI
Pathophysiology of genetically defined dementia and neurodegeneration: Defining therapeutic targets and pathways$1,435,400
P01 · FY2018 · NS
Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$1,334,000
U54 · FY2018 · NS
Data Generation Core - Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$934,287
U54 · FY2018 · NS
Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$833,765
U54 · FY2018 · NS
Nucleocytoplasmic transport and nuclear pore disruption in ALS/FTD$650,895
R01 · FY2018 · NS · contact PI
Oligodendroglial Dysfunction in C9orf72 ALS and FTD$597,360
R01 · FY2018 · NS · contact PI
Regulation of glutamate transport in astrocyte subtypes and in ALS$461,014
R01 · FY2018 · NS
Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells-Supplement$418,818
U54 · FY2018 · NS
Mitigation of nuclear pore dysfunction in c9FTD/ALS pathogenesis$348,955
P01 · FY2018 · NS · contact PI
GLT-1 Enhancers as Drug Candidates for Treating Cocaine Addiction$348,739
R01 · FY2018 · DA
Data Analysis & sig - Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$323,790
U54 · FY2018 · NS
Administration - Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$55,908
U54 · FY2018 · NS
Community Interactions Outreach - Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$20,015
U54 · FY2018 · NS
Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$2,167,765
U54 · FY2017 · NS
Data Generation Core - Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$1,527,239
U54 · FY2017 · NS
Pathophysiology of genetically defined dementia and neurodegeneration: Defining therapeutic targets and pathways$1,481,400
P01 · FY2017 · NS
Nucleocytoplasmic transport and nuclear pore disruption in ALS/FTD$648,990
R01 · FY2017 · NS · contact PI
Oligodendroglial Dysfunction in C9orf72 ALS and FTD$596,524
R01 · FY2017 · NS · contact PI
Data Analysis & sig - Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$520,751
U54 · FY2017 · NS
Regulation of glutamate transport in astrocyte subtypes and in ALS$466,052
R01 · FY2017 · NS
GLT-1 Enhancers as Drug Candidates for Treating Cocaine Addiction$372,311
R01 · FY2017 · DA
ALS/FTD mutant C9orf72-induced genetic and nuclear pathology in iPS cell models$354,375
R01 · FY2017 · NS · contact PI
Mitigation of nuclear pore dysfunction in c9FTD/ALS pathogenesis$296,280
P01 · FY2017 · NS · contact PI
Administration - Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$87,390
U54 · FY2017 · NS
Community Interactions Outreach - Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$32,385
U54 · FY2017 · NS
Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$1,334,000
U54 · FY2016 · NS
Data Generation Core - Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$934,285
U54 · FY2016 · NS
Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$833,765
U54 · FY2016 · NS
Nucleocytoplasmic transport and nuclear pore disruption in ALS/FTD$776,323
R01 · FY2016 · NS · contact PI
Regulation of glutamate transport in astrocyte subtypes and in ALS$464,767
R01 · FY2016 · NS
GLT-1 Enhancers as Drug Candidates for Treating Cocaine Addiction$377,257
R01 · FY2016 · DA
ALS/FTD mutant C9orf72-induced genetic and nuclear pathology in iPS cell models$354,375
R01 · FY2016 · NS · contact PI
Data Analysis & sig - Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$323,788
U54 · FY2016 · NS
Administration - Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$55,910
U54 · FY2016 · NS
Community Interactions Outreach - Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$20,017
U54 · FY2016 · NS
Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$8,498
U54 · FY2016 · NS
Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$1,334,000
U54 · FY2015 · NS
Data Generation Core - Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$934,286
U54 · FY2015 · NS
Regulation of glutamate transport in astrocyte subtypes and in ALS$485,636
R01 · FY2015 · NS
GLT-1 Enhancers as Drug Candidates for Treating Cocaine Addiction$375,351
R01 · FY2015 · DA
ALS/FTD mutant C9orf72-induced genetic and nuclear pathology in iPS cell models$354,375
R01 · FY2015 · NS · contact PI
Data Analysis & sig - Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$317,686
U54 · FY2015 · NS
Administration - Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$55,910
U54 · FY2015 · NS
ALS/FTD mutant C9orf72-induced genetic and nuclear pathology in iPS cell models$40,500
R01 · FY2015 · NS · contact PI
Community Interactions Outreach - Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$26,118
U54 · FY2015 · NS
Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$1,334,000
U54 · FY2014 · NS
Data Generation Core - Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$940,394
U54 · FY2014 · NS
GLT-1 Enhancers as Drug Candidates for Treating Cocaine Addiction$504,440
R01 · FY2014 · DA
ALS/FTD mutant C9orf72-induced genetic and nuclear pathology in iPS cell models$350,830
R01 · FY2014 · NS · contact PI
Data Analysis & sig - Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$310,155
U54 · FY2014 · NS
Administration - Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$55,910
U54 · FY2014 · NS
Community Interactions Outreach - Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells$27,541
U54 · FY2014 · NS
Generation and Characterization of Amyotrophic Lateral Sclerosis$789,962
U24 · FY2013 · NS · contact PI
New hiPSC tools for astroglial-focused approaches to ALS$789,962
U24 · FY2013 · NS · contact PI
ALS/FTD mutant C9orf72-induced genetic and nuclear pathology in iPS cell models$354,375
R01 · FY2013 · NS · contact PI
Astroglial Monocarboxylate Transporter (MCT) Pathway in Neurodegeneration$335,832
R01 · FY2013 · NS · contact PI
Generation and Characterization of Amyotrophic Lateral Sclerosis$849,613
U24 · FY2012 · NS · contact PI
New hiPSC tools for astroglial-focused approaches to ALS$849,613
U24 · FY2012 · NS · contact PI
Astroglial Monocarboxylate Transporter (MCT) Pathway in Neurodegeneration$348,104
R01 · FY2012 · NS · contact PI
Astroglial Monocarboxylate Transporter (MCT) Pathway in Neurodegeneration$347,393
R01 · FY2011 · NS · contact PI
Small Molecule Induced Astrogliogenesis$246,000
R21 · FY2011 · NS · contact PI
Generation and Characterization of Amyotrophic Lateral Sclerosis iPS cells$1,837,375
RC2 · FY2010 · NS · contact PI
Astroglial Monocarboxylate Transporter (MCT) Pathway in Neurodegeneration$369,064
R01 · FY2010 · NS · contact PI
Small Molecule Induced Astrogliogenesis$205,000
R21 · FY2010 · NS · contact PI
Generation and Characterization of Amyotrophic Lateral Sclerosis iPS cells$82,000
RC2 · FY2010 · NS · contact PI
Astroglial Monocarboxylate Transporter (MCT) Pathway in Neurodegeneration$78,467
R01 · FY2010 · NS · contact PI
Characterizing Beta Lactams as Neuroprotectants for Amyotrophic Lateral Sclerosis$1
U01 · FY2010 · NS · contact PI
Generation and Characterization of Amyotrophic Lateral Sclerosis iPS cells$1,862,625
RC2 · FY2009 · NS · contact PI
Neuronal vs. glial glutamate transport regulation in ALS$437,085
R01 · FY2009 · NS · contact PI
Therapeutic Expression of Glial Glutamate Transporters$358,502
R01 · FY2009 · NS · contact PI
Characterizing Beta Lactams as Neuroprotectants for Amyotrophic Lateral Sclerosis$1
U01 · FY2009 · NS · contact PI
Neuronal vs. glial glutamate transport regulation in ALS$424,354
R01 · FY2008 · NS · contact PI
Therapeutic Expression of Glial Glutamate Transporters$358,502
R01 · FY2008 · NS · contact PI
Characterizing Beta Lactams as Neuroprotectants for Amyotrophic Lateral Sclerosis$322,944
U01 · FY2008 · NS · contact PI
Neuronal vs. glial glutamate transport regulation in ALS$411,994
R01 · FY2007 · NS · contact PI
Therapeutic Expression of Glial Glutamate Transporters$358,502
R01 · FY2007 · NS · contact PI
Stem Cell Therapy for Motor Neuron Disease$301,641
R01 · FY2007 · NS · contact PI
Neuronal vs. glial glutamate transport regulation in ALS$411,940
R01 · FY2006 · NS · contact PI
Characterizing Beta Lactams/Neuroprotective Drugs/ALS$402,391
U01 · FY2006 · NS · contact PI
Therapeutic Expression of Glial Glutamate Transporters$369,209
R01 · FY2006 · NS · contact PI
Stem Cell Therapy for Motor Neuron Disease$303,350
R01 · FY2006 · NS · contact PI
Neuronal vs. glial glutamate transport regulation in ALS$409,566
R01 · FY2005 · NS
Characterizing Beta Lactams/Neuroprotective Drugs/ALS$397,419
U01 · FY2005 · NS
Therapeutic Expression of Glial Glutamate Transporters$377,130
R01 · FY2005 · NS
Stem Cell Therapy for Motor Neuron Disease$310,650
R01 · FY2005 · NS
Stem Cell Therapy for Motor Neuron Disease$310,650
R01 · FY2004 · NS
NEURONAL GLUTAMATE TRANSPORTER ASSOCIATED PROTEINS(GTRAP$293,599
R01 · FY2004 · NS
MECHANISMS FOR ABERRANT GLUTAMATE TRANSPORT IN ALS$428,647
R01 · FY2003 · NS
Stem Cell Therapy for Motor Neuron Disease$310,650
R01 · FY2003 · NS
NEURONAL GLUTAMATE TRANSPORTER ASSOCIATED PROTEINS(GTRAP$293,599
R01 · FY2003 · NS
NEURONAL GLUTAMATE TRANSPORTER ASSOCIATED PROTEINS(GTRAP$54,000
R01 · FY2003 · NS
MECHANISMS FOR ABERRANT GLUTAMATE TRANSPORT IN ALS$54,000
R01 · FY2003 · NS
MECHANISMS FOR ABERRANT GLUTAMATE TRANSPORT IN ALS$418,843
R01 · FY2002 · NS
COPPER CHAPERONE FOR SOD1 (CCS) AND MOTOR NEURON DISEASE$392,022
R01 · FY2002 · NS
NEURONAL GLUTAMATE TRANSPORTER ASSOCIATED PROTEINS(GTRAP$293,599
R01 · FY2002 · NS
ASTROCYTES, RNA METABOLISM AND NEURODEGENERATION$0
P01 · FY2002 · AG
MECHANISMS FOR ABERRANT GLUTAMATE TRANSPORT IN ALS$399,720
R01 · FY2001 · NS
COPPER CHAPERONE FOR SOD1 (CCS) AND MOTOR NEURON DISEASE$382,910
R01 · FY2001 · NS
NEURONAL GLUTAMATE TRANSPORTER ASSOCIATED PROTEINS(GTRAP$293,722
R01 · FY2001 · NS
MECHANISMS FOR ABERRANT GLUTAMATE TRANSPORT IN ALS$50,000
R01 · FY2001 · NS
ASTROCYTES, RNA METABOLISM AND NEURODEGENERATION$0
P01 · FY2001 · AG
MECHANISMS FOR ABERRANT GLUTAMATE TRANSPORT IN ALS$391,497
R01 · FY2000 · NS
COPPER CHAPERONE FOR SOD1 (CCS) AND MOTOR NEURON DISEASE$374,729
R01 · FY2000 · NS
NEURONAL GLUTAMATE TRANSPORTER ASSOCIATED PROTEINS(GTRAP$310,336
R01 · FY2000 · NS
MECHANISMS FOR ABERRANT GLUTAMATE TRANSPORT IN ALS$50,000
R01 · FY2000 · NS
ASTROCYTES, RNA METABOLISM AND NEURODEGENERATION$0
P01 · FY2000 · AG